Professional Documents
Culture Documents
in Gene Therapies
p
for Rare Diseases
May 6, 2015
M d
Moderator:
t
Mike Rice, MS, MBA
Senior Consultant, Defined Health
Panelists:
Matthew Porteus, MD, PhD
Associate Professor of Pediatrics
(Cancer Biology), Stanford University
Stewart Abbot, PhD
Executive Director, Integrative Research at
Celgene Cellular Therapeutics (CCT)
Paul Gallagher, MBA
President, Compass Strategic Consulting
`
Todays
y Web Panel Discussion
Is Co-Hosted by:
Defined Health is a
leading knowledgebased business
development
p
strategy
gy
consultancy to pharma
and biotech.
BIO is the
world's largest trade
association representing
biotechnology
gy
organizations
across the world.
BIO also organizes the
BIO International
Convention which will
Convention,
be held in Philadelphia
from June 15-18.
ShareVault is a
full-featured,
state-of-the-art
virtual data room that
allows organizations
to simply and
securely share
sensitive documents
with external parties
in the cloud.
Logistics
Mike Rice
MS, MBA
Senior Consultant
Defined Health
Mike Rice
2004
2014
Z
Zocor
(simvastatin)
( i
t ti ) - MRK
Seretide/Advair (fluticasone;
salmeterol) - GSK
Zyprexa
yp
((olanzapine)
p ) - Lillyy
Seretide/Advair (fluticasone,
salmetero)
l t ) - GSK
Avastin (bevacizumab) Roche
Herceptin (trastuzumab) Roche
0
EvaluatePharma
Bi l i
Biologic
5,000
10,000 15,000
Protein
Augmentation
Plasma/tissue
derived
proteins
SMIs
Chaperones
Substrate
Reduction
Transcription /
Translation
enhancers
Epigenetics
E i
i
Recombinant
Recombinant
Proteins
Clotting
factors
Cytokines
Hormones
H
Growth
factors
Enzyme
R l
Replacement
Antibodies
Peptidesand
NucleicAcids
Plasmaderived
Polyclonal Igs
Immune
Modulators
Monoclonal
antibodies
Exon skipping
GeneCorrection
& Augmentation
Viralvectors
Retro/
Lentiviral
AdV
AAV
Antisense
mAB fragments
RNAi /miRNA
Scaffolds
Intrabodies
A
Aptamers/
t
/
Ribozyme
Nonviral
Plasmids/
Fragments
Geneediting
with
Meganucleases
ZincFingers
TALENS
CRISPR/Cas9
CellTherapy/
Regen Med
Autologous
andallogeneic
BMT/Cell
therapy
Othercell
sources: e.g.
ES,iPS
D
Devices
i
Encapsulation
Scaffolds
Implants
Microorgans
Aphaeresis
A h
i
FDA.gov
Gene Transfer
Vectors
Retro/Lentiviral
HSV, VACV, SV40
Plasmid/Fragment
Liposome, Other?
Vaccines
Gene
Therapy
Clinical
Need
Monogenic Disease
Infectious Disease
Polygenic Diseases
Oncology
Suicide Gene
Gene Augmentation
Antisense, RNAi
Therapeutic
Intervention
14
13 6
28
203
28
28
29
33
39
Adis R&D Insight,
Thomson Reuters Cortellis
69
56
Oncology
Sensory Disorders
M t b li Disorders
Metabolic
Di d
Cardiovascular Disorders
Neuromuscular Disorders
Hematological Disorders
Neurological Disorders
Neurodegenerative Disorders
Infectious Disease
Immunological Disorders
Musculoskeletal Disorders
Other
Gastrointestinal Disorders
Liver Disorders
Skin Disorders
Genitourinary Disorders
Congenital Disorders
Lung Disorders
Accidents & Injury
Respiratory Disorders
Lymphatic Disorders
13
5
9 7
14
Adenovirus
15
122
Lentiviral vector
Plasmid
15
Cancer vaccine
16
Fragment/DNA
R
Retroviral
i l
23
T cell therapy
Cell therapy
Other viral vector
38
Oncolytic virus
65
49
10
ZF
Transposon
TALEN/CRISPR
Therapeutic Intervention:
Transient
Stable
Enzyme (ERT)
Autologous Cell
Correction
mRNA
ASO / RNAi
Random
Directed
Exon Skipping
Plasmid Transfection
Recombination
mRNA
Viral Integration
Gene Activation
Viral Episomal?
Gene Editing
Triplex
Other epigenetic
11
Allo SCT
Transposons
Meganucleases, ZF,
CRISPR, TALENs,
CRISPR
TALENs SSODN
Cross-Comparison of
Gene
Ge
e Therapy
e apy Platforms
at o s
Technology
Adenovirus
(AdV)
AdenoAssociated
Vi
Virus
(AAV)
Retrovirus
Lentivirus
Gene
Editing
Capacity
< 8kB
< 5kB
< 8kB
8-10kB
n/a
Delivery*
I vivo
In
i
In vivo
Ex vivo
Ex vivo
Ex vivo
Integration
Pros/Cons
E i
Episomal
l
Episomal
Integrating
Integrating
Integrating
14
Gene Editing
AAV
AdV
LentiLenti
Retro
Plasmid
Other
Partners
15
Adoptive
p
Cellular I/O
/
Numberr of Papers P
Published E
Each Year
Adeno-Associated Virus
Retroviral
CRISPR
ZZN/ZFPs
Adenoviral
Lentiviral
TALEN
Meganucleases
1,400
1,200
1,000
800
600
400
200
1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013
PubMed
16
Broadly Applicable, Cancer is By Far the Most Active Area for Clinical Trials
Monogenetic Diseases May Be Most Tractable
Gene Therapies by All Phases of Development
n = 574, individual products counted multiple times
13
68
Preclinical
Phase 1/2
Phase 2
Phase 3
158
329
Registered
Marketed
17
Thecombinedregenerativemedicinefield,includingcell,gene,
andgenemodifiedcelltherapies,generated$4.74Bthrough
partnering deals acquisitions and public and private
partneringdeals,acquisitions,andpublicandprivate
investmentsfromMarch2013toMarch2014.
Therearecloseto700clinicaltrialscurrentlyunderwaywiththe
largest areas of focus in oncology CNS disorders and
largestareasoffocusinoncology,CNSdisorders,and
cardiovasculardiseases.And,theclinicalpipelineismaturing
withoveronethirdofthosetrialsinlaterstages(P2orP3).The
rateofgrowthisreflectedinthepublicmarkets:25%ofthe
biotechIPOsinthesecondhalfof2013wereregenerative
medicinecompanies.
http://www.biospace.com/News/biotech-ipos-up-22-since-bubble-year-of-2000-shows/361523; http://www.poliwogg.com/news/125-sectors-to-watchin-biotech-and-healthcare-investing
18
VC Financing
2015
2014
2013
EvaluatePharma
19
2012
2011
June 2014
$44M
Acquisition
2013
July 2013
$40M
Familial lipoprotein
lipase deficiency
EvaluatePharma, Company Website
20
June 2014
Aug 2014
Dec 2014
Jan 2015
$252M
$4M
$280M
$6M
Hemophilia A Acquisition Hemophilia B Hemophilia A&B
2014
July 2014
$1M
CV
Apr 2015
$64M
VC Funding
2015
Jan2015
$11M+
$
CRISPR
platform
Feb 2015
$845M
Parkinsonss
Parkinson
Disease
April 2015
$1B
S100A1
CV
$5.7B
6,000
ZioPharm
5,000
GenVec
IPO Amo
ounts ($M)
$4.3 B
AmpliPhi Biosciences
4,000
Intrexon
$3.07B
3,000
Celladon
AGTC
2,000
UniQure
$897M
1 000
1,000
A l
Avalanche
h
Spark
0
AAV
Bloomberg.com
oo be g co
21
AdV
Lenti
ZF
Feb2014
$150M
CART
June2014
$350M
TCR
Sept2014
$350M
Dec2014
TargetedTcells $20M
CART
Jan2015
$525M
CART
Jan2015
$60M
CART
Jan2015
$150M
CART
Mar2015
CART
Opus Bio
2014
Jan2014
$13.5M
Acquisition
June2014
$265M
CART
22
Sept2014
CART
2015
Oct2014
TCRms
Dec2014
$11m
CART
Feb2015
CART,TCR
Mar2015
CART
Apr2015
CART
ZioPharm
20,000
Takara Bio
18,000
Sangamo Biosciences
$17B
MolMed
16,000
MacroGenics
14,000
Lion Biotechnology
Kite Pharma
12,000
Juno Therapeutics
10,000
Emergent Biosolutions
$8.6B
8,000
6,000
Bluebird Bio
4,000
Bellicum
$2 3B
$2.3B
2,000
$1.2B
$797M
Atara Biotherapeutics
$536M
0
Bi-specific
Bloomberg.com
Bl
b
23
CAR T
TCR
CTL
Other T cell
therapy
TIL
Affimed Therapeutics
24
Translation of p
preclinical results into man
RAC review
M
Manufacturing:
f t i
R
Reproducibility,
d ibilit Scalability,
S l bilit High
Hi h costt off goods
d
25
https://www.genomeweb.com/research-funding/nih-places-human-germline-out-bounds-genome-editing-funding
26
http://ir.celladon.com/releasedetail.cfm?releaseid=908592
27
28
ttps //
ge o e eb co / esea c u d g/
p aces u a ge
e out bou ds ge o e ed t g u d g
https://www.genomeweb.com/research-funding/nih-places-human-germline-out-bounds-genome-editing-funding
29
Introduction:
30
Matthew Porteus
Introduction
31
Stewart Abbot
C ll l Therapeutics
Cellular
Th
ti
D
Developing
l i cell,
ll gene-modified
difi d cellll and
d tissue
ti
therapeutics
th
ti
33
Mechanistic studies
Viral transduction stable cell lines for in vitro and in vivo functional studies
34
Celgene collaborations with bluebirdbio and BCM-CAGT leveraging CCT manufacturing and
R&D capabilities
Pharma Approaches to
Individualized Treatments
Rare Disorders
7,000
,
different rare diseases and disorders,, 30 million people
p p in the United
States are living with rare diseases
35
Pharma Approaches to
Individualized Treatments
CCTs Experience
Potentiall for
f rationally-designed
ll d
d therapeutics
h
to be
b curative
or at least
l
transformative
Assumption that high treatment effects can facilitate smaller clinical trials
36
Pharma Approaches to
Individualized Treatments
CCTs Experience (continued)
37
Pharma Approaches to
Individualized Treatments
38
Pharma Approaches to
Individualized Treatments
Summary
Large-pharma
Large
pharma increasing comfortable with advanced gene
gene-based
based
therapeutics
39
Introduction:
40
President,
Compass Strategic Consulting, Inc.
Paul Gallagher
41
There is not just one business model for all gene therapies.
Different diseases will find different models
Jorn Aldag, CEO, UniQure
42
43
Prioritize developing strong clinical, economic and longterm follow-up data based on early analysis of gene
therapy HTAs
Discussion and
Q&A
Listeners, please type your questions into the
Q&A interface in GoToWebinar.
GoToWebinar
44
Panelists:
Matthew Porteus, MD, PhD
Associate Professor of Pediatrics
(Cancer Biology), Stanford University
Stewart Abbot, PhD
Executive Director, Integrative Research at
Celgene Cellular Therapeutics (CCT)
Paul Gallagher, MBA
President, Compass Strategic Consulting
`
45
46